Details of the Drug

General Information of Drug (ID: DMWUG4L)

Drug Name

PRAX-562

Synonyms

Relutrigine; PRAX-562; 2392951-29-8; 3-[Ethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-[1,2,4]triazolo[4,3-a]pyrazine; relutrigine [INN]; AW5C5XHM4W; PRAX562; SCHEMBL23132181; GTPL12643; BFXBSYMVTNEFRF-UHFFFAOYSA-N; EX-A7203; HY-148792; CS-0641132; 1,2,4-TRIAZOLO(4,3-A)PYRAZINE, 3-(ETHOXYDIFLUOROMETHYL)-6-(5-FLUORO-6-(2,2,2-TRIFLUOROETHOXY)-3-PYRIDINYL)-; 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3- yl][1,2,4]triazolo[4,3-a]pyrazine

Indication

Disease Entry	ICD 11	Status	REF
Epileptic encephalopathy	8A62	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C15H11F6N5O2
Canonical SMILES: CCOC(C1=NN=C2N1C=C(N=C2)C3=CC(=C(N=C3)OCC(F)(F)F)F)(F)F
InChI: InChI=1S/C15H11F6N5O2/c1-2-28-15(20,21)13-25-24-11-5-22-10(6-26(11)13)8-3-9(16)12(23-4-8)27-7-14(17,18)19/h3-6H,2,7H2,1H3
InChIKey: BFXBSYMVTNEFRF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 147075611
TTD ID: D7UW0X

References

1	ClinicalTrials.gov (NCT05818553) A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE). U.S.National Institutes of Health.